|

CTX-009 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: Tovecimig

Pipeline

Phase 1/2: 2

Top Sponsors

  • Washington University School of Medicine1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • Metastatic Biliary Tract Cancer1
  • Glioblastoma1

St Louis, Missouri1 trial

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Washington University School of Medicine

Phase 1/2

Houston, Texas1 trial

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.